PDCD1 and non-small cell lung carcinoma: In this study, we demonstrated that combination therapy of a PD-1 inhibitor and SMI significantly improved antitumor efficacy and prolonged survival without increasing irAEs in the LLC mouse and NCI-H226 HuNCG mouse models, providing preclinical evidence for a new combination therapy strategy for NSCLC.